SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3

• CAT Number: I040909
• CAS Number: 1373170-36-5
• Molecular Formula: C78H95N9O20
• Molecular Weight: 1478.64
• Purity: ≥95%
• Synonyms: [4-[[(2S)-2-[[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethoxy]acetyl]amino]-6-[[(4-methoxyphenyl)-diphenylmethyl]amino]hexanoyl]amino]phenyl]methyl [(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl] carbonate
• InChI: InChI=1S/C78H95N9O20/c1-4-62-63-48-60(88)25-28-67(63)85-72-64(62)50-87-69(72)49-66-65(74(87)92)52-105-75(93)77(66,5-2)107-76(94)106-51-55-19-23-59(24-20-55)83-73(91)68(18-12-13-29-81-78(56-14-8-6-9-15-56,57-16-10-7-11-17-57)58-21-26-61(95-3)27-22-58)84-71(90)54-104-53-70(89)80-30-32-96-34-36-98-38-40-100-42-44-102-46-47-103-45-43-101-41-39-99-37-35-97-33-31-82-86-79/h6-11,14-17,19-28,48-49,68,81,88H,4-5,12-13,18,29-47,50-54H2,1-3H3,(H,80,89)(H,83,91)(H,84,90)/t68-,77-/m0/s1
• InChIKey: CNYMUXFAKRSPCQ-BWZHNGFGSA-N
• SMILES: CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)OC(=O)OCC5=CC=C(C=C5)NC(=O)C(CCCCNC(C6=CC=CC=C6)(C7=CC=CC=C7)C8=CC=C(C=C8)OC)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN=[N+]=[N-])C2=NC9=C1C=C(C=C9)O

SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3(CAT: I040909) is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound consists of SN38, a potent chemotherapeutic agent derived from irinotecan, linked to a polyethylene glycol (PEG)-based linker for enhanced solubility and stability. The PAB (para-aminobenzyl) group and the lysine (Lys) modification with MMT (a protecting group) facilitate the conjugation of the drug to antibodies, enabling targeted delivery to cancer cells. Upon internalization, the linker is cleaved, releasing the active SN38, which then exerts cytotoxic effects on tumor cells. This compound is particularly relevant for Cancer Disease Research, especially in the development of targeted therapies for cancers such as colorectal cancer, where irinotecan and its active form SN38 are commonly used.